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LL-37 is a cationic host defense peptide that is highly expressed during acute inflammation and that kills
bacteria by poorly defined mechanisms, resulting in permeabilization of microbial membranes. High concen-
trations of LL-37 have also been reported to have cytotoxic effects against eukaryotic cells, but the peptide is
clearly capable of differentiating between membranes with different compositions (eukaryotic versus bacterial
membranes). Eukaryotic cells such as leukocytes change their membrane composition during apoptotic cell
death, when they are turned into nonfunctional but structurally intact entities. We tested whether LL-37
exerted specific activity on apoptotic cells and found that the peptide selectively permeabilized the membranes
of apoptotic human leukocytes, leaving viable cells unaffected. This activity was seemingly analogous to the
direct microbicidal effect of LL-37, in that it was rapid, independent of known surface receptors and/or active
cell signaling, and inhibitable by serum components such as high-density lipoprotein. A similar selective
permeabilization of apoptotic cells was recorded for both NK cells and neutrophils. In the latter cell type,
LL-37 permeabilized both the plasma and granule membranes, resulting in the release of both lactate
dehydrogenase and myeloperoxidase. Apoptosis is a way for inflammatory cells to die silently and minimize
collateral tissue damage by retaining tissue-damaging and proinflammatory substances within intact mem-
branes. Permeabilization of apoptotic leukocytes by LL-37, accompanied by the leakage of cytoplasmic as well
as intragranular molecules, may thus shift the balance between pro- and anti-inflammatory signals and in this
way be of importance for the termination of acute inflammation.
The cathelicidins form a large family of microbicidal, cat-
ionic host defense peptides found in all mammalian species
examined so far, including humans, cows, pigs, rabbits, sheep,
mice, monkeys, and horses (60). Only one human cathelicidin,
human cationic antimicrobial protein 18 (hCAP-18; unproc-
essed form), or LL-37 (the predominant, mature antibacterial
form), has been isolated. LL-37 is mainly expressed by neutro-
phils and epithelial cells during acute inflammation. LL-37 is
stored as a propeptide in the specific granules of neutrophils.
Upon neutrophil activation, the proform is cleaved enzymati-
cally by proteinase 3 to the active form during degranulation
toward the extracellular compartment (49). The concentration
of LL-37 can be severely increased at sites of inflammation,
and levels up to about 15 to 25 g/ml have been reported in
bronchoalveolar lavage fluid from infants with pulmonary in-
fections as well as from cystic fibrosis patients (14, 45); even
higher levels (over 1 mg/ml) has been reported from psoriatic
skin lesions (40).
LL-37 was originally identified as a cationic microbicidal
peptide due to its ability to specifically permeabilize prokary-
otic membranes (1, 16, 31); it possesses direct microbicidal
activity against bacteria, fungi, and enveloped viruses (5, 33).
Very high concentrations of LL-37 have also been reported to
have cytotoxic effects against eukaryotic cells in vitro (28). The
microbial killing mechanism is dependent on the membrane-
active properties of the peptide, which has the ability to inter-
act with both the inner and the outer membranes of gram-
negative bacteria (22). The mode of action for the direct
microbicidal activity of host defense peptides has not been
determined conclusively, but the leading hypothesis is that
these peptides are membrane active and have the ability to
break the integrity of bacterial cell membranes more or less
selectively over eukaryotic membranes (47). Bacterial mem-
branes are composed of phospholipids different from those of
eukaryotic cell membranes, with the bacterial membranes be-
ing more negatively charged than their eukaryote counterparts.
The presence of surface molecules other than phospholipids,
e.g., lipopolysaccharide (LPS; an outer membrane component
of gram-negative bacteria), is also of importance to the overall
negative charge of bacterial membranes. This negative charge
is, in part, believed to be a determinant for the interaction with
cationic peptides and gives the peptides selectivity for the mi-
crobial membranes (37).
Lately, LL-37 has been shown to have immunomodulatory
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properties, in addition to its microbicidal potential (10), and is
also capable of activating various immune cells; thus, it pos-
sesses a functional dualism that is also displayed by certain
other cationic peptides (7, 13, 51, 58). Among the numerous
immunomodulatory actions displayed by LL-37, chemoattrac-
tion and the induction of chemokine release from leukocytes,
the stimulation of angiogenesis, and the binding and neutral-
ization of bacterial LPS can be found (9). LL-37 has been
shown to be highly upregulated under inflammatory condi-
tions, particularly those involving the skin, e.g., psoriasis (20,
40). During inflammation, it is of vital importance that the
activities of the cells involved are tightly regulated. Many in-
flammatory leukocytes, especially neutrophils, are packed with
a variety of cytotoxic substances aimed at microbial killing, and
if these substances reach the extracellular environment in an
uncontrolled fashion, the risk of tissue destruction and sus-
tained inflammation are increased (25, 56). One important
means of ridding the system from potentially harmful intracel-
lular constituents is by apoptosis of the inflammatory cells,
followed by phagocytic clearance of the corpse by viable
phagocytes (34, 44). Apoptosis is often called the physiological,
programmed form of cell death, characterized by the lack of
proinflammatory actions and the minimization of damage to
surrounding cells and tissue. Apoptotic cells are nonfunctional
but, importantly, carry an intact cell membrane that prevents
the uncontrolled leakage of intracellular molecules (25). De-
spite the integrity of the apoptotic cell membrane, its surface-
exposed molecule composition differs substantially from that
of the membranes of viable cells. One prominent example of
surface changes relates to phospholipids. In viable cells, an
uneven distribution of phospholipids between the two leaflets
of the double-sided membrane is maintained by an energy-
dependent process that keeps the negatively charged phospha-
tidylserine (PS) on the inside. In a nonfunctional apoptotic
cell, the PS distribution is leveled out over time, with the PS
also being on the outer leaflet as a result (35), making the
membrane of apoptotic cells more negatively charged and, in
this way, more like the membrane of bacteria. The surface-
located PS is also an important “eat-me” flag that ensures
phagocytic clearance of the apoptotic cell (18). Annexin V is a
Ca2-dependent, cell-impermeant protein with a high affinity
for PS. When it is conjugated to a fluorochrome, it is widely
used for the detection and quantification of apoptosis by flow
cytometry.
Given the ability of LL-37 to distinguish between prokary-
otic and eukaryotic membranes and the fact that the compo-
sition of eukaryotic membranes changes when a cell becomes
apoptotic, we investigated whether the peptide could distin-
guish between viable and apoptotic leukocytes. Using primary
human neutrophils, a cell type that has a short half-life in vivo
and that rapidly enters apoptosis in culture, we found that
LL-37 selectively permeabilized the membranes of apoptotic
cells under serum-free conditions, leaving viable cells unaf-
fected in this respect. A specificity similar to that for apoptotic
cells was also found for NK cells, another inflammatory leu-
kocyte, which was rendered apoptotic by treatment with hy-
drogen peroxide. The selective permeabilization of apoptotic
neutrophils was very rapid and seemingly independent of
known LL-37 surface receptors and/or active cell signaling.
Peptide-induced permeabilization in effect shifted apoptotic
cells into a necrotic phenotype, whereby intracellular constit-
uents were released into the extracellular milieu; leakiness was
effectively counteracted by the presence of human serum or
high-density lipoprotein (HDL) in a similar manner, as micro-
bial killing by LL-37 was blocked by these substances. The
mere surface exposure of the negatively charged PS, a conse-
quence of apoptosis, was not responsible for the selective per-
meabilization of apoptotic cells. We concluded that LL-37
possesses selective permeabilizing activity on apoptotic leuko-
cytes in a manner seemingly analogous to its activity against
bacterial membranes. In pathological settings with high levels
of cathelicidin expression in the absence of serum constituents
(such as psoriatic lesions), the permeabilization of apoptotic
leukocytes by LL-37 could be of importance in determining the
eventual outcome of acute inflammation.
MATERIALS AND METHODS
Reagents. LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES)
was synthesized by N-(9-fluorenyl)methoxycarbonyl chemistry at the Nucleic
Acid/Protein Service Unit at the University of British Columbia (Vancouver,
British Columbia, Canada). Scrambled LL-37 (sLL-37; RSLEGTDRFPFVRLK
NSRKLEFKDIKGIKREQFVKIL) was purchased from CSS-Albachem Ltd.
(East Lothian, United Kingdom). WKYMVM was from Alta Bioscience (Bir-
mingham, United Kingdom), and WRW4 was from Genscript Corp. (Scotch
Plains, NJ). Hp(2-20) was synthesized and purified by high-pressure liquid chro-
matography (Innovagen, Lund, Sweden). Ficoll-Paque was from Pharmacia
(Uppsala, Sweden), and Ficoll-Hypaque was from Nycomed (Oslo, Norway).
Dextran was purchased from Amersham Biosciences (Uppsala, Sweden). The
A-6013 agarose used for the casting of all plates for the inhibition zone assays
was from Sigma Chemical Co. (St. Louis, MO), as were oxidized ATP (oxATP),
HDL, cytochalasin B, lidocaine, colchicine, and calcein. The antibody -CD95
was from Nordic BioSite (Ta¨by, Sweden). Annexin V-fluorescein isothiocyanate
(FITC), annexin V-allophycocyanin (APC), 7-amino-actinomycin D (7-AAD),
and the BD IMag NK cell isolation kit were supplied by BD Biosciences (San
Jose, CA). RPMI 1640 medium was from PAA Laboratories (Pasching, Austria).
The lipids used for liposome preparation (1,2-dipalmitoyl-sn-glycero-3-phos-
phatidylethanolamine [DPPE], 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine
[DPPC], 1,2-dipalmitoyl-sn-glycero-3-phosphatidyl-rac-glycerol, sodium salt
[DPPG], dioleoyl-sn-glycero-3-phosphatidylserine [DOPS], and cholesterol)
were purchased from Larodan (Malmo¨, Sweden).
Isolation and culture of human cells. Human neutrophils were isolated by a
standard technique (11, 12) from buffy coats obtained from the blood of healthy
donors at the Sahlgrenska Hospital, Gothenburg, Sweden. In short, dextran
sedimentation was performed at 1  g, followed by hypotonic lysis of the re-
maining erythrocytes and centrifugation in a Ficoll-Paque gradient. Thereafter,
the neutrophils were washed twice and resuspended in RPMI 1640 medium
supplemented with 10% fetal calf serum to a density of 5  106 cells/ml. Cells
(500 l) were added to polypropylene tubes and incubated at 37°C in 5% CO2 for
20 h for the induction of spontaneous apoptosis. For increased apoptosis, azide-
free -CD95 monoclonal antibody (10 g/ml) was coincubated with the cells,
which resulted in approximately 20% viable neutrophils and 80% apoptotic
neutrophils.
For the isolation of NK cells, peripheral venous blood was incubated with
Iscove’s modified Dulbecco’s medium, dextran, and acid citrate dextrose for 15
min at room temperature. The supernatant was centrifuged through a Ficoll-
Hypaque (Lymphoprep) density gradient, and the mononuclear cells at the
interface were collected and further processed by countercurrent centrifugal
elutriation (57). In short, this technique allows cell separation on the basis of the
cell sedimentation rate in a spinning rotor at 2,150 rpm balanced by a counter-
directed flow through a chamber. By varying the flow rate, different cell fractions
were separated on the basis of their sizes. The NK-cell-enriched lymphocyte
fractions were collected at flow rates of between 14 and 15 ml/min, and the cells
were then further isolated through negative selection with magnetic beads (BD
IMag NK cell isolation kit), according to the instructions provided by the man-
ufacturer. Finally, the isolated NK cells were incubated overnight in Iscove’s
modified Dulbecco’s medium supplemented with 10% normal human serum at
37°C in 5% CO2. For the induction of the early apoptotic characteristics in the
NK cells, 100,000 to 200,000 cells incubated overnight were exposed to 200 M
H2O2 for 6 h at 37°C in 5% CO2 (23, 24, 53).
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Evaluation of apoptosis. The neutrophils that had been incubated overnight,
as described above, were washed and resuspended in annexin V binding buffer
(AVBB; 1 mM HEPES, 14 mM NaCl, 0.25 mM CaCl2; pH 7.4) to 6.25  106
cells/ml. Samples (70 l) were stained with 5 l annexin V-FITC for 5 min at
ambient temperature, whereupon 7-AAD was added, and the staining was con-
tinued for 10 min before the addition of AVBB to give a final volume of 500 l.
In some experiments, annexin V-FITC was exchanged for -CD16–FITC: 100-l
samples were stained with 10 l antibody for 10 min at 0°C, whereupon staining
with 7-AAD was performed as described above. Peptides diluted in water were
added 5 min prior to analysis, if not indicated otherwise. HDL (650 g/ml),
bovine serum albumin (0.5%; wt/vol), or 10% salt mimicking serum salt (11.3
mM NaCl, 2.4 mM NaHCO3, 0.06 mM MgCl2, 0.13 mM CaCl2, 0.39 mM KCl)
(28) was added to the indicated samples before the addition of peptide. Samples
were analyzed by fluorescent-activated cell sorter analysis before and after the
addition of peptides. For samples treated with the formyl peptide receptor-like
1 (FPRL1) antagonist, WRW4 (5 M) was added 5 min (at 37°C) prior to the
addition of peptide. The same procedure was used for the P2X7 inhibitor oxATP
(900 M), but by the procedure with oxATP, the samples were preincubated with
the inhibitor for 30 min. The concentrations and incubation times for the inhib-
itors have previously been shown to specifically block Ca2 flux induced through
FPRL1 and P2X7, respectively (15). The inhibitors of membrane repair cytocha-
lasin B (10 g/ml), colchicine (10 M), or lidocaine (5 mM) were coincubated
with the cells overnight and were added to all buffers used for the subsequent
experiments, as indicated.
The H2O2-treated NK cells were washed and resuspended in AVBB. Each
sample was stained at ambient temperature with 5 l annexin V-FITC for 5 min,
followed by staining with 5 l 7-AAD, for a final volume of 100 l, for another
10 min. The samples were thereafter diluted to 300 l with AVBB before
analysis. Flow cytometry was performed before and 5 min after the addition of
LL-37 (5 g/ml was used for NK cells, as these cells are more susceptible than
neutrophils to the cytotoxic action of LL-37).
Determination of direct microbicidal activity. Escherichia coli strain MG1655
was grown overnight in Luria-Bertani (LB) broth (3) at 37°C on a rotary shaker.
A modified inhibition zone assay was used for the detection of direct microbi-
cidal activity (21, 26, 27). In short, standard LB agar (LB broth supplemented
with 1% [wt/vol] agarose) containing bacteria (approximately 5  105 CFU in
logarithmic growth phase per milliliter agar) was poured into petri dishes (di-
ameter, 92 mm). Wells (diameter, 3 mm; depth, 1 mm) were punched in the agar,
and peptide preparations (3 l) diluted in distilled water were added to the wells,
whereupon the plates were incubated at ambient temperature for 45 min and
then at 37°C overnight. The peptide was used in the assays at amounts ranging
from 1.88 g/well to 7.5 g/well. Inhibition zones were calculated as the diameter
of the clear zones, free of visible bacteria, surrounding the wells. HDL (650
g/ml) was added to the agar plates before the plates were cast.
Liposome preparation. Lipids (DPPE, DPPC, DPPG, and cholesterol) were
dissolved in chloroform-methanol (1:1) to a concentration of 20 mg/ml. DOPS
was dissolved in chloroform to 25 mg/ml. The lipid mixtures (final concentration
of total lipids, 2.5 mM) were dissolved in chloroform-methanol (1:1) and dried
under reduced nitrogen pressure at 45°C, with subsequent drying under vacuum
for 1 h. Liposomes containing the following were prepared: DPPE-DPPC-cho-
lesterol (1:1:1; lipids typically found in eukaryotic membranes), DPPE-DPPG
(7:3; phospholipids typically found in bacterial membranes), and DPPE-DPPC-
cholesterol-DOPS (3:3:3:1; lipids typically found in eukaryotic plasma mem-
branes with 10% PS). During the subsequent preparation steps, the liposomes
were kept at 50°C at all times to avoid solidification of the dipalmitoyl lipids. The
dried lipid film was dissolved in 1 ml Tris buffer (150 mM NaCl, 10 mM Tris, 1
mM EDTA; pH 7.4) containing self-quenching concentrations of calcein (80
mM), and the mixture was vigorously vortexed and then given a short sonication.
Large unilamellar vesicles were obtained by passing the suspension 20 times
through 400-, 200-, and 100-nm-pore-size polycarbonate filters (Eschborn, Ger-
many) on a handheld extruder. Extraliposomal calcein was removed by filtration
through Sephadex G-50 resin. The release of calcein to the extraliposomal
medium upon peptide addition was monitored continuously by measuring the
fluorescence intensity on a Perkin-Elmer LS55 fluorescence spectrometer (exci-
tation , 494 nm; emission , 513 nm). The maximum fluorescence intensity,
which corresponded to 100% leakage, was determined by adding Triton X-100
(0.1%) to the liposomes.
Intracellular Ca2 measurements. Intracellular Ca2 was measured by a pre-
viously described method (42). In short, neutrophils incubated overnight for the
induction of apoptosis were resuspended in cell loading medium (1% fetal calf
serum in Krebs-Ringer phosphate buffer containing glucose [10 mM glucose, 1
mM Ca2, 1.5 mM Mg2; pH 7.3]) and loaded with Fluo-3 (4 mg/ml) and
Fura-Red (10 mg/ml) reagents at 37°C for 30 min. The cells were washed twice,
resuspended in AVBB to a final concentration of 6  106/ml, and stained with
annexin V-APC at ambient temperature for 15 min. The samples were diluted to
8.75  105 cells/ml, and 0.5 ml was prewarmed at 37°C for 5 min. The level of
intracellular Ca2 accumulation in individual cells upon the addition of WK
YMVM (107 M) was assessed by flow cytometry over 5 min. The fluorescence
emissions of the Fluo-3 and Fura-Red reagents were measured in the FL-1 and
the FL-3 channels, respectively. The data were analyzed by using the kinetics
mode of FlowJo software (version 5.7.1; FlowJo, LLC, Ashland, OR), and the
relative intracellular Ca2 concentration was presented as the ratio between the
mean fluorescence intensity of the Fluo-3 reagent and that of the Fura-Red
reagent over time. The analysis of Ca2 accumulation was performed after gating
of viable and apoptotic cells by the use of annexin V-APC staining.
To establish that the apoptotic neutrophils were properly labeled with the
Fluo-3 and Fura-Red reagents, ionomycin (500 nM) was included as a positive
control stimulus. This ionophore forms pores in the plasma membrane, giving
rise to an artificial, signaling-independent rise in the intracellular calcium con-
centration. Addition of ionomycin resulted in an increase in the intracellular
calcium concentration in the apoptotic cells as well as the viable cells (data not
shown).
Measurements of LDH and MPO release from LL-37-treated neutrophils.
Neutrophils (5  106/ml) were incubated overnight in 5% CO2 at 37°C, and
-CD95 (10 g/ml) was included for the induction of apoptosis or was not
included. The cells were washed and diluted to 1  106/ml before treatment with
LL-37 (50 g/ml) for 10 min. All samples were divided in two, and one portion
of each sample was lysed with Triton X-100 (1%) for 1 min, after which the cell
debris was removed by centrifugation. The amount of the cytosolic enzyme
lactate dehydrogenase (LDH) released was measured with a cytotoxicity detec-
tion kit from Roche Diagnostics GmbH (Mannheim, Germany), according to the
manufacturer’s directions. The myeloperoxidase (MPO) content in the neutro-
phils was measured by determination of the amount of enzyme activity by mixing
50 l of the cell supernatants described above with 100 l peroxidase substrate
(1,2-phenylenediamine dihydrochloride [Dako Denmark A/S]) in a 96-well plate
and incubation of the plate overnight at room temperature. The absorbance at
492 nm was then measured.
Statistical analysis. The results are expressed as means  standard deviations
(SDs). Unpaired and paired t tests were used for statistical analysis, and P values
are two tailed with 95% confidence intervals. For comparisons of multiple data
sets, one-way analysis of variance with Bonferroni’s multiple-comparison tests
was performed. The data were analyzed with GraphPad Prism software (version
4.02; GraphPad Software, San Diego, CA).
RESULTS
Direct microbicidal action of LL-37 and discrimination be-
tween membranes of different compositions. LL-37 is a host
defense peptide with dual actions that both works directly by
permeabilizing microbial membranes and has receptor-de-
pendent, immunomodulatory actions on leukocytes as a
means of protecting against infections. The direct microbi-
cidal effects of LL-37 and the sLL-37 control peptide against
E. coli were assessed in inhibition zone assays; LL-37 in-
duced a clear zone around the well that was free of visible
bacteria, while sLL-37 had no direct microbicidal effect (Fig.
1A). The lethal concentration was calculated to 6.3 g/ml
for E. coli (strain MG1655) under the specific medium con-
ditions used in the assay. The lethal concentration was de-
termined from the diameter of the inhibition zone by a
previously described method (26) and was defined as the
lowest concentration that just inhibited colony formation in
the thin agar plates. Under the serum-free conditions used,
LL-37 (100 g/ml) had no effect on the integrity of the cell
membranes of freshly prepared neutrophils, as shown by a
lack of 7-AAD staining (Fig. 1B). This dye is incapable of
passing intact cell membranes and therefore functions as a
useful marker of membrane integrity (46). These experi-
ments show that LL-37 can be directly microbicidal in the
5-g/ml range (as determined by calculation of the lethal
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concentration from the results obtained from the inhibition
zone assays), whereas concentrations up to 100 g/ml were
not cytotoxic for neutrophils under serum-free conditions.
To further characterize the ability of LL-37 to discriminate
between bacterial and eukaryotic membranes, we tested the
effect of LL-37 on liposomes containing the lipids typically
found in bacterial as well as in eukaryotic membranes in a
calcein release assay. Bacterial membranes are slightly more
negatively charged than eukaryotic membranes, and liposomes
containing large amounts of neutral PE and the negatively
charged phosphatidylglycerol (PG) were synthesized. For the
eukaryotic membrane-like liposomes, cholesterol was incorpo-
rated together with the two neutral phospholipids PE and PC.
As expected, LL-37 readily permeabilized the bacterial mem-
brane-like liposomes (Fig. 1C). The eukaryotic membrane-like
liposomes were permeabilized to a limited extent (approxi-
mately 15%), but they were obviously much more resistant
than the bacterial membrane-like liposomes to the lytic action
of LL-37. Taken together, these data show that LL-37 is clearly
capable of differentiating between membranes with different
compositions.
Selective permeabilization of apoptotic neutrophils by LL-37.
LL-37 had no cytotoxic effect on freshly prepared human neu-
trophils (Fig. 1B). In order to study the effect of LL-37 on
viable and apoptotic membranes of primary leukocytes, we
employed human neutrophils, which gradually enter spontane-
ous apoptosis during in vitro culture. In this set of experiments,
neutrophils incubated overnight spontaneously entered apop-
tosis, leaving a mixed population of cells with 66% viable cells
(annexin V negative, 7-AAD negative) and 31% apoptotic cells
(annexin V positive, 7-AAD negative), as assessed by flow
cytometry (Fig. 2A, left panel). By use of this standardized
protocol, very few cells (less than 3%) displayed a necrotic
phenotype with permeable membranes, as indicated by the
lack of 7-AAD-positive events. The use of this mixed culture
enabled us to investigate viable and apoptotic cells simulta-
neously, and addition of LL-37 (50 g/ml, 5 min of incubation)
to the mixed population selectively permeabilized the apop-
totic cells that acquired the 7-AAD stain under serum-free
conditions (Fig. 2A, middle panel, upper right quadrant). The
membranes of annexin V-negative cells were still intact (7-
AAD negative) after the addition of peptide (Fig. 2A; middle
panel, lower left quadrant). sLL-37 (50 g/ml, 5 min of incu-
bation) did not permeabilize any cell type (Fig. 2A, right
panel), indicating that the cationic nature of LL-37 is not
sufficient to permeabilize apoptotic neutrophils. sLL-37 at a
FIG. 1. LL-37 can distinguish between membranes with different compositions. (A) The direct microbicidal activity of LL-37 (1.88, 3.75, and
7.5 g/well) against E. coli was determined in an inhibition zone assay. LL-37 gave rise to clear, bacteria-free zones around the wells (upper panel),
while sLL-37 (1.88, 3.75, and 7.5 g/well) was inactive (lower panel). (B) Freshly separated neutrophils were not sensitive to the direct microbicidal,
lytic action of LL-37 (100 g/ml), as shown by the lack of 7-AAD fluorescence intensity plotted against the forward scatter. 7-AAD is a nucleic
acid stain used for the detection of the loss of membrane integrity in cells. The results of one experiment with the percentage of cells in each region
are shown. (C) LL-37 (5 ng/ml) readily permeabilized bacterial membrane-like liposomes (gray line) composed of PE-PG (7:3), while the
eukaryotic membrane-like liposomes (black line), composed of PE-PC-cholesterol (1:1:1), were more resistant to the permeabilizing effect of
LL-37. The percentage of total calcein released, as assessed by the addition of Triton X-100, is plotted against time. The means  SDs (n  3)
obtained at 0, 50, 100, 150, and 200 s are shown. The amounts of calcein released at 100, 150, and 200 s were compared; and significant differences
between the amounts released were was established (P 	 0.01 at each point, as indicated [**]; n  3). The arrow indicates the time of addition
of peptide.
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concentration of 500 g/ml was also ineffective (data not
shown).
In order to rule out the possibility that an undefined inter-
action between LL-37 and annexin V caused the permeabili-
zation, experiments were conducted with CD16 instead of an-
nexin V as a marker for neutrophil apoptosis (Fig. 2B, left
panel). CD16 is a surface protein present on viable neutrophils
(Fig. 2B, left panel, lower right quadrant) that is lost upon
apoptosis (Fig. 2B, left panel, lower left quadrant), and only
cells negative for CD16 (i.e., apoptotic cells) became 7-AAD
positive after addition of peptide (Fig. 2B, right panel). After
addition of LL-37, the apoptotic cell population was permeant
not only to the nuclear dye 7-AAD but also, apparently, to the
-CD16 antibody that gained access to intracellular CD16 and,
as a result, conferred a CD16 signal to the permeabilized cells
(Fig. 2B, right panel).
Selective permeabilization of apoptotic NK cells by LL-37.
Inflammatory cells other than neutrophils have the ability to
enter apoptosis as well. NK cells are cytotoxic, large granular
lymphocytes important for eradicating viruses and combating
tumor cells. One efficient way to drive NK cell apoptosis is to
subject these cells to extracellular reactive oxygen species (23).
To test whether the selective permeabilization of apoptotic
cells applied only to neutrophils or if it represents a more
general mechanism that acts on other leukocytes as well, NK
cells were isolated and subjected to H2O2 treatment for the
induction of apoptosis. Untreated NK cells incubated for 6 h
displayed only 5% apoptotic cells, as assessed by annexin V
and 7-AAD labeling (Fig. 3A). When the cells were coincu-
bated with H2O2 (200 M), a larger population (17%) became
apoptotic (Fig. 3B), resulting in a mixed population of viable
and apoptotic NK cells. A population of NK cells (16%) also
appeared to be permeabilized after the addition of H2O2 (Fig.
3B, upper right quadrant). After this mixed population was
washed, it was treated with LL-37 (5 g/ml, 5 min of incuba-
tion), and with these leukocytes, the apoptotic cells were also
FIG. 2. Selective permeabilization of apoptotic neutrophils by LL-37. (A) Neutrophils incubated for 20 h spontaneously entered apoptosis,
resulting in 66% viable cells and 31% apoptotic cells, as assessed by annexin V and 7-AAD staining and visualized by flow cytometry (left panel).
When LL-37 (50 g/ml) was added to these cells, all apoptotic (annexin V-positive) cells were permeabilized (7-AAD positive), while the viable
(annexin V-negative) population was unaffected (middle panel) 5 min after addition of the peptide. sLL-37 (50 g/ml) was inactive when it was
added to the system (right panel). The results presented here represent those of one of three experiments performed for this experimental series.
(B) Apoptosis was also assessed by CD16 shedding (left panel). Only the apoptotic neutrophils (CD16 negative) were permeabilized by the
addition of LL-37 and stained positive for 7-AAD. The -CD16 antibody also gained access to intracellular CD16 upon permeabilization, as shown
by the increase in the fluorescence intensity of CD16 (right panel). The plots represent those from one of two independent experiments that were
performed. Each plot shows the means  SDs from one representative experiment.
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primarily permeabilized (Fig. 3C). When the results for the
LL-37-treated viable population were compared to those for
the H2O2-treated control cells, no significant difference was
found (P  0.07; n  3). A lower standard concentration of
LL-37 was used against the NK cells than against the neutro-
phils (5 g/ml and 50 g/ml, respectively), owing to the fact
that NK cells were more susceptible to the cytotoxic action of
LL-37. At 10 g/ml, a substantial amount of cytotoxicity
against NK cells was observed (the proportion of viable cells
dropped from 82.6% to 38.5%; data not shown). At 5 g/ml of
LL-37, mainly apoptotic (annexin V-positive) NK cells were
permeabilized, whereas the permeabilization of viable cells
was not statistically significantly reduced. These data indicate
that the selective permeabilization of apoptotic cells is inde-
pendent of the type of leukocyte.
Characterization of selective permeabilization. Dose titra-
tion experiments revealed that the permeabilizing effect on
apoptotic neutrophils was concentration dependent starting at
approximately 10 g/ml, and a full effect was reached at 50
g/ml of LL-37. The half-maximal effective concentration
(EC50) was determined for the selective permeabilization of
apoptotic cells by plotting the mean value of the percentage of
apoptotic cells at concentrations 0, 5, 10, and 50 g/ml for
three separate experiments and fitting a straight line to the
data set (R2  0.99); the EC50 for the permeabilization of
apoptotic neutrophils was 27 g/ml. At 500 g/ml, a more
general cytotoxic effect was observed; in addition to the per-
meabilization of all apoptotic cells, viable neutrophils were
also affected (Fig. 4A) (P 	 0.001 compared to the results for
viable neutrophils treated with buffer). The EC50 was also
determined for the cytotoxic action of LL-37 against viable
cells by plotting the mean value of the percentage of viable
cells obtained after treatment with LL-37 at concentrations of
0, 5, 10, 50, 100, and 500 g/ml from three separate experi-
ments. A straight line was fitted to the data set (R2  0.97), the
trend line was extrapolated, and the EC50 was determined to
be 700 g/ml. Due to technical limitations, we could not use
concentrations of LL-37 higher than 500 g/ml. On the basis of
EC50s, the concentration needed for the permeabilization of
viable neutrophils (general cytotoxicity) was found to be ap-
proximately 25 times higher than that needed for the perme-
abilization of apoptotic neutrophils. Time and titration exper-
iments showed that the specificity was intact (i.e., viable cells
were unaffected) for at least the first 5 min (P
 0.05 compared
to the results obtained by treatment with buffer alone). Almost
all annexin V-positive cells became leaky within 5 min of LL-37
addition (Fig. 4B). In an attempt to study the leakage within
the first 5 min, we analyzed the process (7-AAD fluorescence)
kinetically in a flow cytometer, having first gated the cells on
the basis of annexin V staining (Fig. 4C, left panel). Increased
7-AAD staining was apparent immediately after addition of
LL-37 (Fig. 4C, right panel) in the annexin V-positive cells
(red), whereas the annexin V-negative population (green)
never became 7-AAD positive. These results again showed that
only apoptotic cells were permeabilized by LL-37 and that the
leakage started immediately after addition of peptide.
Cationicity alone was not sufficient to confer direct micro-
bicidal action (Fig. 1A) or specific permeabilization (Fig. 2A,
right panel), since sLL-37 displayed no activity in these assays
(at the highest concentrations used of 7.5 g/well and 500
g/ml, respectively). We next tested the direct microbicidal
and immunomodulatory peptide Hp(2-20), which combines
cationicity with an alpha-helical nature, i.e., classical features
of cationic host defense peptides (13). This peptide was unable
to permeabilize leukocytes (viable or apoptotic) up to concen-
trations of 2 mM (data not shown), showing that the selective
action described for LL-37 is not a general feature of cationic,
alpha-helical host defense peptides.
The effect of LL-37 on apoptotic neutrophils is independent
of known surface receptors and Ca2 signaling. LL-37 has
been reported to employ a variety of surface receptors for the
mediation of its immunomodulatory effects; for neutrophils,
two of the most likely receptor candidates are FPRL1 and
P2X7 (17, 39). We used the antagonists WRW4 (4) and oxATP
(38) to block FPRL1 and P2X7, respectively. In the presence of
these two antagonists, the apoptotic cells were still permeab-
FIG. 3. Selective permeabilization of apoptotic NK cells by LL-37. (A) Isolated NK cells were incubated for 6 h and stained with annexin V
and 7-AAD. Only a small amount of cells displayed apoptotic characteristics (4.7  1.2%; n  3). (B) When the cells were incubated in the
presence of H2O2 (200 M) for 6 h, the population of apoptotic NK cells increased (16.8  3.3%; n  3). The population of permeabilized NK
cells also increased upon addition of H2O2 (from 5.3  2.2% to 16.0  4.2%; n  3). (C) When LL-37 (5 g/ml) was added to the H2O2-treated
NK cells, the apoptotic population was permeabilized and stained positive for 7-AAD, in accordance with the results seen for neutrophils. At this
concentration, no significant permeabilization of the viable population compared to that for the population treated with H2O2 alone was seen (P
0.07; n  3).
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ilized (Fig. 5A), indicating that the permeabilization was inde-
pendent of known surface receptors. According to the general
dogma, apoptotic cells are nonfunctional and should thus be
unable to transmit intracellular signals (2). When FPRL1 and
P2X7 are activated, they transmit signals that result in the
mobilization of intracellular calcium (15). Using flow cytom-
etry with mixed neutrophil samples containing both viable and
apoptotic cells, we gated the cells on the basis of annexin V
staining and measured the intracellular calcium mobilization in
both types of cells simultaneously (Fig. 5B). Stimulation of the
mixed population with the potent FPRL1 ligand WKYMVM
resulted in a classic intracellular calcium flux (Fig. 5B, right
panel) for the viable cells (green), whereas the apoptotic cells
(red) were completely unresponsive. These data indicate that
the permeabilizing effect of LL-37 on apoptotic cells is most
likely independent of surface receptors and/or active cell sig-
naling. In this respect, the permeabilizing effect was different
from other (mostly receptor-dependent) immunomodulatory
effects on leukocytes reported previously (10). In conclusion,
the effect of LL-37 on apoptotic leukocytes is closely related to
the direct microbicidal, permeabilizing effect of LL-37 rather
than immunomodulating, receptor-dependent effects.
Inhibition by serum components. We hypothesized that the
mechanism behind the observed specific permeabilization of
apoptotic cells by LL-37 had more in common with its direct
microbicidal effects than its immunomodulatory actions. The
direct microbicidal effect of LL-37 is known to be inhibited by
various serum components like HDL and apolipoprotein A1
(32, 55), and in our microbicidal assay, the presence of HDL
also markedly inhibited bacterial killing by the peptide. When
HDL was added to the inhibition zone plates at levels expected
to be found in serum (650 g/ml), the inhibition zone size
generated by LL-37 was markedly decreased (Fig. 6A).
We next subjected a mixed population of neutrophils (viable
and apoptotic) to LL-37 in the presence or the absence of
either 10% human serum or HDL (650 g/ml). Both serum
and HDL completely blocked the LL-37-induced permeabili-
zation of apoptotic neutrophils (Fig. 6B). The immunomodu-
latory, receptor-dependent effects of LL-37 have previously
been shown to be intact in the presence of serum (17), in which
HDL is a prominent protein. These data further strengthen the
hypothesis that the observed effect is, in fact, receptor inde-
pendent. When a salt solution composed to mimic the compo-
sition of 10% serum or bovine serum albumin (0.5%; wt/vol)
was added, no inhibitory effects were observed (data not
shown). These data imply that the presence of proteins in
general and serum salts does not impair the function of LL-37.
Negatively charged PS is insufficient to mediate membrane
permeabilization by LL-37. One plausible cause of the specific
action of LL-37 on apoptotic cells could be the changes in
membrane composition that accompany apoptosis, such as the
surface exposure of the phospholipid PS. This negatively
charged molecule could theoretically confer an affinity for the
positively charged peptide, similar to the reported electrostatic
interaction between LL-37 and LPS (30, 31). We checked
whether LL-37 displays a direct affinity for PS by testing
whether it binds to phospholipids and glycosphingolipids im-
mobilized on a solid phase (50). When an attempt was made to
bind LL-37 to total lipid extracts from human erythrocytes (40
g) and control mixtures of acid glycosphingolipids from var-
ious sources (40 g each), which were separated on thin-layer
chromatograms, or to pure PE, PC, and PS (4 g each), no
specific binding of LL-37 to any of these compounds was ob-
served (data not shown). In a microtiter well assay, the anionic
GM1 ganglioside
[Gal3GalNAc4(NeuAc3)Gal4Glc1Cer] and the neutral
phospholipid PE were included as controls. LL-37 exerted no
specificity toward PS compared to its specificity toward the
other two lipids found in eukaryotic membranes included in
this assay (data not shown).
We next checked whether the presence of PS could contrib-
ute to making membrances sensitive to the lytic action of
LL-37 by incorporating PS into liposomes containing the phos-
pholipids typically found in eukaryotic membranes and subse-
quently measuring the level of calcein leakage after addition of
the peptide. The incorporation of PS into liposomes containing
FIG. 4. The permeabilizing effect of LL-37 on neutrophils is con-
centration dependent and rapid. (A) Different concentrations of LL-37
ranging from 0 to 500 g/ml were tested; increased concentrations led
to an increased permeabilizing effect on the apoptotic cells, and at 500
g/ml, a more general cytotoxic action that also affected viable neu-
trophils was observed. The percentage of cells is plotted against the
LL-37 concentration; and the populations were viable (blue), apoptotic
(red), and permeabilized (black). Mean SDs (n 3) are shown. The
results for each population were compared to those for an untreated
sample, and significance was established, as indicated, by analysis of
variance and Bonferroni’s test for multiple comparisons. (B) Within 5
min after the addition of LL-37 (50 g/ml), the permeabilizing action
was complete. The membranes of viable cells retained their integrity
for at least 5 min. The percentage of cells is plotted against time; and
the populations were viable (blue), apoptotic (red), and permeabilized
(black). Mean  SDs (n  3) are shown. Statistical significance was
determined as indicated above for panel A. (C) After the gating of
viable (green) and apoptotic (red) cells with the aid of annexin V
staining (left panel), the increase in the intensity of 7-AAD staining
after the addition of LL-37 (50 g/ml) was monitored in real time.
Only the apoptotic cells displayed an increase in 7-AAD intensity
(right panel), and the permeabilization started immediately following
addition of the peptide (arrow). The results represent those of one of
two experiments that were performed. **, P 	 0.01; ***, P 	 0.001.
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phospholipids typically found in eukaryotic membranes did not
confer any permeabilizing activity on LL-37 (Fig. 7). The total
amounts of calcein released (determined by calculation of the
area under the curve) for the two liposome preparations were
determined and when the means were compared, no significant
difference between the two was found (P  0.08; n  3).
The presence of PS did not change the susceptibilities of the
liposomes to the lytic activity of LL-37, and the peptide did not
seem to have any direct affinity for PS. We next hypothesized
that LL-37 does not have any specific affinity for the apoptotic
cells but instead interacts with both viable and apoptotic cells
to the same extent and in this way induces limited membrane
damage. The differences in the outcomes would then be due to
the fact that the nonfunctional apoptotic cells are unable to
repair the disturbed membrane, whereas the viable cells are
quick to reseal the disruption. Viable cells are equipped with a
complex machinery that allows them to repair membrane dam-
age, and that machinery often involves a variety of cytoskeletal
FIG. 5. The effect of LL-37 on neutrophils is independent of known receptors and Ca2 signaling. (A) A mixed population of viable and
apoptotic neutrophils was treated with the two antagonists WRW4 (5 M) and oxATP (900 M), which antagonize two known LL-37 neutrophil
receptors, FPRL1 and P2X7, respectively. In the presence of the antagonists, LL-37 (50 g/ml) still permeabilized apoptotic, annexin V-positive
cells. Paired t tests were performed to establish statistical significance (n  3). (B) An overnight preparation of incubated neutrophils was assessed
for annexin V staining, and a mixed population of both viable (green) and apoptotic (red) neutrophils (left panel) was shown. The mixed population
was stimulated with the potent neutrophil FPRL1 ligand WKYMVM (107 M), and the transient Ca2 release was monitored by flow cytometry.
The viable cells (green line) responded with a rise in the intracellular Ca2 concentration, while the apoptotic cells (red line) were totally
irresponsive. The results of one representative experiment are shown. The FL-1/FL-3 ratio was plotted against time (right panel). *, P	 0.05; ***,
P 	 0.001.
FIG. 6. The permeabilizing effect of LL-37 on apoptotic neutrophils is inhibited by human serum and HDL. (A) When HDL (650 g/ml) was
added to the inhibition zone plates, the clear zone surrounding the well after the addition of LL-37 (1.88 g/well) decreased markedly. (B) In a
control experiment, apoptotic neutrophils were readily permeabilized by the addition of LL-37 (50 g/ml; left panel). When LL-37 was added to
cells in a solution containing 10% normal human serum, the permeabilizing effect was totally blocked (middle panel). The addition of HDL (650
g/ml) to the neutrophil population prior to the addition of LL-37 (50 g/ml) also inhibited the permeabilizing effect of LL-37 on apoptotic
neutrophils (right panel). Representative plots from three independent experiments and means  SDs summarized from three independent
experiments are shown.
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filaments such as actin and microtubuli (36). We therefore
subjected mixed neutrophil populations containing both viable
and apoptotic cells to different inhibitors of cytoskeletal fila-
ment function in order to see whether such treatment would
also enable the permeabilization of viable cells. Treatment of
cells with cytochalasin B (which inhibits actin polymerization)
(29) or colchicine (which perturbs microtubule assembly) (8)
before addition of LL-37 did not make the viable cells sensitive
to the lytic action of LL-37 (data not shown). In addition, the
local anesthetic lidocaine, which is known to modify cell mem-
brane fluidity (59), did not alter the pattern of susceptibility to
LL-37; i.e., the peptide still permeabilized only the annexin
V-positive cells (data not shown).
Permeabilization of apoptotic cells by LL-37 is associated
with leakage of intracellular as well as intragranular constit-
uents. Among the inflammatory leukocytes, neutrophils harbor
an especially potent arsenal of proteolytic enzymes that could
be very harmful to surrounding cells and tissues if they were
released in an uncontrolled fashion. Apoptotic cells with an
intact cell membrane retain their intracellular substances, and
to see if permeabilization by LL-37 resulted in true leakage, we
measured the extracellular presence of the cytoplasmic enzyme
LDH. Peptide treatment of mixed neutrophil samples resulted
in the release of LDH, and the levels of release correlated well
with the level of apoptosis in the original cell sample; -CD95-
treated cells (74.8  2.0% apoptotic cells; mean  SD, n  3)
released significantly more LDH (P  0.009) after addition of
LL-37 than the spontaneously apoptotic cells did (35.5  4.9%
apoptotic cells; mean  SD, n  3) (Fig. 8A).
Most potent enzymes of neutrophils are, however, not stored
in the cytoplasm but, rather in intracellular, membrane-en-
closed granules such as the azurophil granules (19). We looked
at the release of the azurophil granule protein MPO from
-CD95-treated neutrophils and found that LL-37 indeed pro-
voked the release of significant amounts of MPO from these
cells (Fig. 8B). Taken together, these data show that LL-37 is
able to permeabilize the cell membranes of apoptotic neutro-
phils, leading to the leakage of cytoplasmic contents. In addition,
the fact that MPO was released from LL-37-treated apoptotic
neutrophils also indicates that the granular membranes are per-
meabilized, facilitating the extracellular release of various poten-
tially deleterious substances.
DISCUSSION
The human cathelicidin LL-37 was originally identified as a
cationic alpha-helical antibacterial peptide capable of micro-
bial killing mediated by its interaction with the microbial mem-
branes (1, 16, 31). Clearly, the peptide is capable of distin-
guishing between membranes with different compositions, and
eukaryotic cells are much less susceptible to membrane attacks
from LL-37 than, e.g., bacterial membranes. More recently, it
has also been shown that LL-37 is capable of modulating the
activity of several important immune cells (9). Similar to cer-
tain other peptides (7, 13, 51, 58), LL-37 displays a functional
dualism, in that it directly kills microbes and modulates im-
mune cell function; both of these activities are likely important
for host defense. It is well known that leukocytes change the
composition of their membranes during, e.g., apoptotic cell
death. The differences between the membranes of viable and
apoptotic cells relate not only to the expression of various
surface proteins but also to their phospholipids compositions
(35). On the basis of these facts and the ability of LL-37 to
distinguish between different types of membranes, we reasoned
that the peptide could possibly discriminate between viable
and apoptotic leukocytes. Primary human neutrophils gradu-
ally enter apoptosis spontaneously during in vitro culture, en-
abling easy access to mixed cell samples containing both viable
and apoptotic cells from the same donor. We thus used neu-
trophils as a model cell and showed that LL-37 selectively
induced the permeabilization of apoptotic neutrophils, leaving
the viable cells intact. In addition, a similar pattern of selective
FIG. 7. The selectivity of LL-37 for lysis of apoptotic cells is inde-
pendent of PS exposure. Liposomes containing typical eukaryotic lip-
ids were prepared without PS (green line) or with 10% PS (red line).
LL-37 (5 ng/ml) was added, as indicated by the arrow, to the different
liposomes, and calcein leakage was monitored over time. The intro-
duction of PS in liposomes containing the phospholipids typically
found in eukaryotic membranes had no effect. The percentage of total
calcein released, as assessed by the addition of Triton X-100, is plotted
against time. The ranges for the two data sets are shown. The total
amount of calcein released over 225 s (determined from the area under
the curve) was established and did not differ significantly (P  0.08;
n  3) between the two types of liposomes.
FIG. 8. Release of LDH and MPO from LL-37-treated apoptotic
neutrophils. (A) Neutrophils were incubated together with or without
the apoptosis inducer -CD95; the result was 75% apoptotic cells and
45% apoptotic cells, respectively, in this set of experiments. These cells
were treated with 50 g/ml of LL-37 for 10 min, and the amount of the
cytosolic enzyme LDH released was measured. It corresponded well
with the fraction of apoptotic cells seen for each treatment, indicating
the complete release of LDH from apoptotic neutrophils. Means 
SDs (n  3) are shown. Statistical significance was established by an
unpaired t test. (B) The release of the intragranular matrix protein
MPO was also measured in -CD95-treated neutrophils. The amount
of MPO released was significantly higher for LL-37-treated cells than
for untreated cells. Means  SDs (n  3) are shown. A paired t test
was used for statistical analysis. **, P 	 0.01.
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permeabilization of apoptotic cells was seen for NK cells ren-
dered apoptotic by hydrogen peroxide treatment, indicating
that the effect was not limited to neutrophils. NK cells were
more susceptible to the lytic action of LL-37, and at concen-
trations higher than 5 g/ml, LL-37 displayed a more general
cytotoxicity against purified NK cells. Viable neutrophils were
not permeabilized until LL-37 concentrations exceeded 100
g/ml, and it makes sense that neutrophils, being important
reservoirs for LL-37, should be more resistant to peptide-
induced membrane disruption.
The immunomodulatory actions of LL-37, as opposed to its
direct microbicidal effects, are primarily mediated by receptor
binding. The surface receptors most often implicated in LL-
37-mediated responses in neutrophils are the chemoattractant
receptor FPRL1 (17) and the nucleotide receptor P2X7 (39).
Antagonists for these receptors, WRW4 (an antagonist of
FPRL1 [4] and oxATP (an antagonist of P2X7 [38]), did not
affect the LL-37-induced permeabilization of apoptotic neu-
trophils, nor did they influence the susceptibilities of viable
cells. These findings suggest that neither FPRL1 nor P2X7 is
involved in the specific permeabilization of apoptotic cells. We
also showed that the apoptotic cells in our mixed neutrophil
samples were completely unable to mobilize intracellular cal-
cium in response to FPRL1 activation, indicating that these
cells are, in fact, nonfunctional and incapable of transmitting
intracellular signals. Taken together, the permeabilization of
apoptotic cells is highly unlikely to depend on the interaction
of LL-37 with surface receptors or even active signal transduc-
tion. This makes the effect of LL-37 on apoptotic leukocytes
appear to be much more like its direct microbicidal action than
its immunomodulatory functions. The fact that the presence of
blood constituents (serum or HDL) that inhibit LL-37’s direct
microbicidal effect was also effective at blocking the permeabi-
lization of apoptotic cells supports this view.
LL-37 has previously been shown to inhibit apoptosis (39) as
well as promote the necrosis (6) of human neutrophils, and it
is likely that the induction of secondary necrosis could explain
the former finding, as was proposed in a study published during
the preparation of the manuscript (61). In line with this, our
data presented here imply that in the presence of LL-37, cells
that spontaneously enter apoptosis are rapidly permeabilized
and are eventually lost from subsequent analyses. The viable
cells, however, would be unaffected by the peptide, resulting in
an apparent enrichment of viable cells at the expense of
apoptotic cells, which could lead to the false impression that
LL-37 inhibits apoptosis. We also show that the LL-37-induced
permeabilization of apoptotic cells destroys the integrity of the
plasma membrane, as seen by the leakage of the cytoplasmic
enzyme LDH to the extracellular space. In addition, we could
also see the leakage of MPO, which is stored in the azurophil
granules (19). Since this granule type is responsible for storing
most of the proteolytic enzymes (19) as well as the immuno-
modulatory molecules, this finding is important and indicates
that LL-37-mediated permeabilization could be a potent
means of getting such substances out to an extracellular loca-
tion. The functional consequences of releasing tissue-destroy-
ing enzymes in combination with molecules that facilitate
wound healing remain to be determined. Interestingly, the
levels of MPO released were lower than anticipated, on the
basis of the proportion of apoptotic cells; it is possible that
LL-37 interacts electrostatically with anionic membrane com-
ponents and sticks to the plasma membrane during perme-
abilization. The permeabilization of azurophil granules could
also require a time longer than the time required for perme-
abilization of the plasma membrane. One must also take into
account the possible release of hCAP-18 from the specific
granules in neutrophils upon permeabilization. If LL-37 is
cleaved extracellularly by proteinase 3, the accumulation of
additional LL-37 could result in a positive-feedback loop.
The mere cationicity of a peptide is not sufficient to induce
specific permeabilization, since sLL-37 was inert in terms of
direct microbicidal activity as well as in the permeabilization of
apoptotic cells. Cationicity combined with an alpha-helical
structure was also not enough to permeabilize apoptotic cells,
since Hp(2-20) did not possess this ability, even though it
potently kills bacteria (43). This Helicobacter pylori peptide is
in many ways similar to LL-37 and also shares specificity for
FPRL1 as a neutrophil receptor (13). We first hypothesized
that flipping of the negatively charged PS from the inner leaflet
of the lipid bilayer to the outer leaflet could confer suscepti-
bility to the cationic peptide LL-37. Several studies have shown
that cationic peptides have an increased affinity (and killing
capacity) for cancer cells compared to their affinity for healthy
cells and that this is due to the fact that cancer cells have more
negatively charged plasma membranes (54, 62). This charge
difference partly originates from the various amounts of PS
present on the outer leaflet of the plasma membranes (41).
However, our data generated from liposome studies and chro-
matogram binding assays failed to support a direct role for PS.
It is likely that apoptotic membrane changes other than the
flipping of PS could explain the selective action of LL-37 on
the apoptotic membranes.
In striking contrast to most immunomodulatory functions of
LL-37 that are intact or that even depend on the presence of
serum (48), we found that serum completely blocked the per-
meabilization of apoptotic cells. In this respect, the effect that
we describe seems to be much more related to the direct
microbicidal action of LL-37. With this in mind, it is reasonable
to assume that the ability of LL-37 to permeabilize apoptotic
cells in vivo would be of importance mainly at sites devoid of
serum components, such as the skin or the lungs. LL-37 is very
highly expressed in psoriatic scales of the skin and contributes
to keeping the scales free of microbial pathogens (40). In
addition, psoriatic scales are characterized by the continued
presence of neutrophils, indicative of a chronic state of acute
inflammation (52). Our findings that LL-37 induces permeabi-
lization of apoptotic leukocytes, concomitant with the leakage
of both cytoplasmic and granular proteins, could thus help
explain why a state of acute inflammation fails to resolve at
sites rich in LL-37 and deprived of serum components.
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